Immix Biopharma, Inc. (IMMX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 12.7 |
| Open | 12.86 |
| Day High | 13.29 |
| Day Low | 12.02 |
| 52-Week High | 15.1 |
| 52-Week Low | 1.94 |
| Volume | 1.19M |
| Average Volume | 1.85M |
| Market Cap | 660.44M |
| PE | -13.34 |
| EPS | -0.91 |
| Moving Average 50 Days | 11.22 |
| Moving Average 200 Days | 8.68 |
| Change | -0.56 |
Immix Biopharma to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Mar 03, 2026 1:45 PM GMT
LOS ANGELES, CA, March 03, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host investor meetings at t
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
GlobeNewswire Inc.
Jan 28, 2026 1:45 PM GMT
– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting – – Final data expected this year followed by planned BLA s
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Dec 09, 2025 10:45 PM GMT
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refract